1-甲基色氨酸(英語:1-Methyltryptophan)是色氨酸的分解酶吲哚胺2,3-双加氧酶1(简称IDO1,EC 1.13.11.52)的抑制剂。[1]它是一种手性化合物,可作为右旋和左旋对映体存在。
其左旋异构体(左旋1-甲基色氨酸)微弱地抑制IDO1,但也可作为酶底物。
其右旋异构体(右旋1-甲基色氨酸)完全不抑制IDO1,但它可以抑制IDO1的相关酶IDO2[2],并在因IDO1活性而缺乏色氨酸的细胞中恢复mTOR信号。[3]右旋1-甲基色氨酸也称为吲哚莫德(indoximod,或译作因多莫得),目前正在进行癌症治疗的临床试验,例如晚期黑色素瘤。[4]
在2017年8月15日,NewLink Genetics获得了一项涵盖吲哚莫德盐和前药制剂的美国专利,至少在2036年之前享有独占权。[5][6]
- ^ Cady, SG; Sono, M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-3-benzo[b]thienyl-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Archives of Biochemistry and Biophysics. 1991, 291 (2): 326–33. PMID 1952947. doi:10.1016/0003-9861(91)90142-6.
- ^ Metz, R; Duhadaway, J. B.; Kamasani, U; Laury-Kleintop, L; Muller, A. J.; Prendergast, G. C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Research. 2007, 67 (15): 7082–7. PMID 17671174. doi:10.1158/0008-5472.CAN-07-1872 .
- ^ Metz, R; Rust, S; Duhadaway, J. B.; Mautino, M. R.; Munn, D. H.; Vahanian, N. N.; Link, C. J.; Prendergast, G. C. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. OncoImmunology. 2012, 1 (9): 1460–1468. PMC 3525601 . PMID 23264892. doi:10.4161/onci.21716.
- ^ IDO Inhibitors Emerging as New Players on Checkpoint Blockade Scene. Aug 2017. [2023-03-17]. (原始内容存档于2018-03-20).
- ^ NewLink Genetics. finpedia.co. [2019-05-09].
- ^ NewLink Genetics Annual Report (Form 10-K). fintel.io. April 9, 2018 [2023-03-17]. (原始内容存档于2023-03-17).